Back to top

Cardiol Therapeutics (CRDL) Has a New Rating from Brookline Capital Markets

Cardiol Therapeutics received a Buy rating and a $6.00 price target from Brookline Capital Markets analyst Tyler Bussian yesterday. The company’s s...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Cardiol Therapeutics Inc. (CRDL)